OMBERACETAM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H22N2O4
Molecular Weight	318.3676
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)CC2=CC=CC=C2

InChI

InChIKey=PJNSMUBMSNAEEN-AWEZNQCLSA-N

InChI=1S/C17H22N2O4/c1-2-23-16(21)12-18-17(22)14-9-6-10-19(14)15(20)11-13-7-4-3-5-8-13/h3-5,7-8,14H,2,6,9-12H2,1H3,(H,18,22)/t14-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12962045 | http://nootropicsexpert.com/noopept/ | https://www.smartdrugsforthought.com/what-is-noopept/
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12596521 https://examine.com/supplements/noopept/

Noopept (DVD-111) is a peptide promoted and prescribed in Russia and neighbouring countries as a nootropic. Noopept was patented by Russian-based pharmaceutical company JSC LEKKO Pharmaceuticals in the 1996. Research shows Noopept has similar effects, but works differently than other nootropics in the racetam-family. The compound is patented in both the US and Russia with patent of Russian Federation number 2119496, U.S. Patent 5,439,930 issued 8/8/1995. Noopept exhibits a combined neuroprotector effect both in vitro and in vivo. Noopept decreases the extent of necrotic damage caused by photoinduced thrombosis of cortical blood vessels. It was established that the neuroprotector effect of noopept is related to its action upon the well-known "triad", whereby the drug reduces neurotoxic effects of excess extracellular calcium, glutamate, and free radicals. Two additional components of the neuroprotector action of noopept are related to the antiinflammatory and antithrombotic activity.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
neuron apoptotic process 5 Target ID: GO:0051402 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12711349	Inhibitor 8297	1.21 µM [IC50]
glutamate receptor signaling pathway 1 Target ID: GO:0007215 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21476267 \| https://www.ncbi.nlm.nih.gov/pubmed/11177296	Modulator 828
Brain-derived neurotrophic factor 2 Target ID: P23560\|\|\|Q9BYY7 Gene ID: 627.0 Gene Symbol: BDNF Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19240853 \| http://nootropicsexpert.com/noopept/	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cognition disorders 21 Sources: http://nootropicsexpert.com/noopept/ https://www.smartdrugsforthought.com/what-is-noopept/	Primary		Approved 8429	Noopept Approved Use Noopept used for the treatment of patients of different age groups of adults and elderly patients suffering from cognitive impairment and emotional lability of various origins. In particular, the drug can be assigned Noopept after craniocerebral injury and coma, as well as patients with cerebral circulatory insufficiency of various etiologies including encephalopathy and asthenic disorders. Noopept can be assigned to improve the cognitive functions of memory, concentration and learning ability in patients with increased physical, intellectual and emotional loads.

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

Recommended Noopept dosage is 10 – 30 mg per day. Noopept is sold in tablet, capsule and powder form. Tablets and capsules are usually 10 mg each.

Route of Administration: Oral

In Vitro Use Guide

Noopept (GVS-111) significantly increased neuronal survival after H(2)O(2)-treatment displaying a dose-dependent neuroprotective activity from 10nM to 100 microM, and an IC(50) value of 1.21+/-0.07 microM.

Name

Type

Language

OMBERACETAM

Official Name

English

Omberacetam [WHO-DD]

Common Name

English

GVS-111

Code

English

omberacetam [INN]

Common Name

English

N-PHENYLACETYL-L-PROLYLGLYCINE ETHYL ESTER

Systematic Name

English

J759.455K

Code

English

NOOPEPT

Common Name

English

Classification Tree Code System Code

DSLD

3380 (Number of products:17)